Skip to main content
NewslettersWatchlist

Jazz Pharma Plc(JAZZ-Q)
NASDAQ

Today's Change
Real-Time Last Update Last Sale Cboe BZX Real-Time

Jazz Pharma Plc

FIFTH FLOOR WATERLOO EXCHANGE WATERLOO ROAD
DUBLIN L2 D04 IRL
P: 011-353-1634
F: 353-163-4785
http://www.jazzpharma.com

Profile

Jazz Pharmaceuticals is a specialty biopharmaceutical company with a focus in the areas of neuroscience & oncology. It derives the majority of its revenues from its sleep disorder drugs' Xywav & Xyrem. Both drugs are approved for treating cataplexy & excessive daytime sleepiness in narcolepsy patients. Other drugs in the company's neuroscience portfolio include' Sunosi, Epidiolex & Sativex. Epidiolex is approved for treating seizures associated with two rare & severe forms of epilepsy' Lennox-Gastaut syndrome & Dravet syndrome. Sativex is approved in the U.K. & Canada as a treatment for symptom improvement in adult patients with moderate-to-severe spasticity due to multiple sclerosis. Jazz's oncology portfolio includes two drugs' Defitelio for the treatment hepatic veno-occlusive disease with renal or pulmonary dysfunction following hematopoietic stem cell transplantation & Vyxeos for the treatment of adults with two types of acute myeloid leukemia. It received approval for two new drugs' Zepzelca & Rylaze'.

Key Executives

NameTitle
Bruce C. CozaddCEO/Chairman of the Board/Co-Founder/Director
Patricia CarrCFO/Chief Accounting Officer/Senior VP

More from The Globe

The close: Stocks higher as investors focus on Fed moves
Traders work on the floor at the New York Stock Exchange (NYSE) in New York City, U.S., April 26.
The close: Major North American indexes rise as megacap tech stocks rally
A trader works on the floor at the New York Stock Exchange (NYSE) on April 25.
Why this money manager is venturing back into emerging markets and adding more U.S. tech
Illustration of Andrew Pyle for The Mover. Nov. 5, 2022. Illustration by Joel Kimmel
How a Canadian pirate-clad pastor helped ignite Trump Media’s market frenzy
Former President Donald Trump sits in Manhattan Criminal Court in New York, Thursday, April 25.
Activist investor targets Dye & Durham’s ‘underperformance and strategic missteps’ in letter to shareholders
Dye & Durham Ltd. says it has launched a strategic review of its non-core assets in an effort to reduce its debt. The logo for Dye & Durham Ltd. is shown in this undated handout photo. THE CANADIAN PRESS/HO
The close: U.S. stocks fall as GDP report spreads rate-cut gloom; Alphabet surges 15% in post market
Traders work on the floor of the New York Stock Exchange shortly after the opening bell, Wednesday, April 24.
Fiera Capital’s largest shareholder looks to sell stake in company
Jean-Guy Desjardins, global CEO and founder of Fire Capital posses for a portrait at Fiera Capital, in Montreal on Monday, January 8, 2024. Evan Buhler/The Globe and Mail�
The close: S&P 500 higher as markets weigh rising bond yields and upbeat U.S. earnings; TSX lower as rails slide
The Art Deco facade of the original Toronto Stock Exchange building is seen on Bay Street in Toronto in January of 2019.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2024.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Financial data provided by Zacks Investment Research.